Revenue segments as reported by the company.

Product, net

Revenue from anti-CD20 therapeutic programs

Other

Revenue from LEQEMBI Collaboration

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Amortization and impairment of acquired intangible assets

Collaboration profit sharing

(Gain) loss on divestiture of Hillerød, Denmark manufacturing operations

(Gain) loss on fair value remeasurement of contingent consideration

Acquired in-process research and development

Restructuring charges

Other (income) expense, net

Gain on sale of building

Gain on sale of PRV

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Biogen

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Biogen reports Q4 results, focuses on cost-saving and growth strategies

Biogen's Q4 2022 performance showed a revenue decline but an increase in non-GAAP diluted EPS.
The company is prioritizing cost-saving initiatives and strategic product launches for growth.
Challenges include managing expenses, evaluating R&D programs, and balancing cost reductions with investments.
Opportunities lie in upcoming product launches, potential acquisitions, and expanding into new therapeutic areas.

Biogen reports $2.5B revenue in Q1 2023, focuses on transformative drug launches

Biogen's Q1 2023 performance showed revenue stability despite challenges in MS product revenue.
The company's strengths lie in its focus on transformative drug launches and Alzheimer's research advancements.
Challenges include reimbursement expectations and managing the transition period until 2025.
Opportunities exist in external growth strategies, asset prioritization, and commercial launches for LEQEMBI and Zuranolone.

Biogen reports mixed Q2 earnings, LEQEMBI approval drives optimism

Biogen's Q2 2023 Earnings Call showcased mixed financial performance, with a focus on cost-saving initiatives and pipeline advancements. LEQEMBI's approval and positioning as a maintenance treatment offer promise, while challenges in revenue decline and market adoption persist. Strategic initiatives and upcoming milestones provide opportunities for growth and portfolio enhancement.

Biogen reports solid Q3 earnings, eyes regulatory approvals and market expansion

Biogen's Q3 2023 performance reflects steady growth, strategic initiatives, and promising product developments.
Strengths in sustainable growth priorities, product launches, and cost optimization position Biogen for long-term success.
Challenges in market expansion and operational efficiency require focused efforts on infrastructure and process improvements.
Opportunities in regulatory approvals, market expansion, and therapeutic advancements pave the way for future growth and innovation.

Biogen reports Q4 revenue decline but eyes growth opportunities

Biogen's Q4 2023 performance saw revenue decline offset by growth in rare disease revenue.
The company's strategic strengths lie in new product launches, cost reduction initiatives, and a focused pipeline strategy.
Challenges include bottlenecks in product launches and trial size reductions, while opportunities exist in upcoming milestones and market expansion.
Overall, Biogen aims for sustainable growth with a diversified product portfolio and strategic market focus.

Biogen reports robust Q1 earnings, focuses on market expansion

Biogen's Q1 performance reflects strong earnings growth and strategic focus on new launches. Despite challenges in launch processes, the company is capitalizing on market penetration opportunities. With a robust balance sheet and ongoing market expansion efforts, Biogen is poised for continued growth and success.

Biogen reports robust Q2 earnings, eyes growth in new launches

Biogen's Q2 2024 earnings call highlighted strong financial performance, successful product launches, and strategic priorities for growth. While challenges in the MS franchise persist, the company remains focused on sustainable growth through R&D investments and acquisitions. Opportunities for growth exist in expanding product portfolios and upcoming data releases.

Biogen reports mixed Q3 results, focuses on growth strategies

Biogen's Q3 2024 performance was mixed, with revenue growth in key products but overall revenue decline.
The company faces challenges in certain product segments but shows strength in new product development.
Opportunities lie in expanding market presence, new product launches, and potential business development.
Despite profitability challenges, Biogen's focus on growth strategies positions it for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Bayer AG

Bank of New York Mellon

Bristol-Myers

British American Tobacco

Cerner

GlaxoSmithKline

Imperial Brands PLC

Intel

Altria

Merck

Philip Morris

Roche Holding AG

Wide-Moat Stocks On Sale - The October 2020 Heat Map

Bio-Rad Laboratories

CVS Health

Immunomedics

Livongo Health Inc

Moderna

Insulet

Perrigo

QuidelOrtho Corp

These are the healthcare stocks with the best value, fastest growth, and most momentum for October 2020.

Top Healthcare Stocks for October 2020

DaVita

Liberty Media Corp-Liberty SiriusXM

Sirius XM Holdings Inc

STORE Capital

With the market selling off hard and both economic and political uncertainty on the rise, many investors yearn to turn to the most trusted and respected investors in history.

The Best Warren Buffett Stocks To Consider In This Falling Market

Biogen submitted its application for approval of Alzheimer's treatment aducanumab in early July. And it's still targeting a coronavirus treatment with Vir.

Alzheimer's Treatment Fast-Tracked By FDA — Is Biogen Stock A Buy?

AstraZeneca

Momenta Pharmaceuticals

Neoleukin Therapeutics Inc

Relmada Therapeutics Inc

Sanofi

Supernus Pharmaceuticals

Takeda Pharmaceutical

These are the pharmaceutical stocks with the best value, fastest growth, and most momentum for Q4 2020.

Top Pharmaceutical Stocks for Q4 2020

Taiwan Semiconductor Manufacturing

Concerned about the ongoing market turmoil? Here are three stocks to buy and hold through tough times.

Second Coronavirus Market Correction: Where You'll Want to Invest $1,000

Morgan Stanley

Biogen Inc. (BIIB) CEO Michel Vounatsos Presents at Morgan Stanley Global Healthcare Conference (Transcript)

Amgen

These stocks are great anchors for any healthcare investor's portfolio.

2 No-Brainer Stocks to Buy in Biotech

CAMBRIDGE, Mass., Sept.  14, 2020  (GLOBE NEWSWIRE) --   Biogen Inc.  (Nasdaq: BIIB) today announced Healthy Climate, Healthy Lives™, a groundbreaking $250 million, 20-year initiative to eliminate fossil fuels across its operations and collaborate with renowned institutions with the aim to improve health, especially for the world’s most vulnerable populations.

Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health

These drug giants are gearing up for a profitable 2021.

2 No-Brainer Stocks to Buy In Pharma

Alexion Pharma

Gilead Sciences

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The short interest data are out for August 31, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Short Sellers Hike Their Bets in Major Biotechs

CAMBRIDGE, Mass., Sept.  11, 2020  (GLOBE NEWSWIRE) --  Biogen Inc.  (Nasdaq: BIIB) today announced new data underscoring the efficacy and safety of its broad, industry-leading portfolio of multiple sclerosis (MS) therapies. These data will be presented during MSVirtual2020, the eighth joint meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS), which will be held virtually September 11-13, 2020.

New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen’s Industry-Leading MS Portfolio

Royalty Pharma

Although markets have pulled back so far in September, many are viewing this as a technical correction, as the markets ran very hot in a very strong August.

5 Very Undervalued Large Cap Biotech Stocks That Could Explode in 2021

Allstate

Anthem

China Mobile Limited

T. Rowe Price Group

According to the GuruFocus All-in-One Screener, a Premium feature, the following companies have grown their book value per share over the past decade through Sept.

5 Companies Expanding Book Value

CAMBRIDGE, Mass., Sept.  08, 2020  (GLOBE NEWSWIRE) --  Biogen Inc.  (Nasdaq: BIIB) today announced findings from two large, real-world studies that provide insight into the clinical and health disparities that exist for people living with multiple sclerosis (MS). These data, from MS PATHS (Multiple Sclerosis Partners Advancing Technology and Health Solutions) and the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS), will be presented during MSVirtual2020, the eighth joint meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-ECTRIMS), to be held virtually September 11-13, 2020.

New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS

This big pharma has received bad and good news in recent months, but the strength of management may matter more

Biogen: Strong Fundamentals and a 'Modestly Undervalued' Share Price

Canadian Pacific Kansas City Limited

NetEase

O'Reilly Automotive

Companies that have positive and steady net margins and operating margins are often good investments because they can return a solid profit to investors.

5 Undervalued Stocks of Profitable Businesses

Abbott Labs

Johnson & Johnson

Here Are Warren Buffett's Favorite Coronavirus Stocks

Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating).

Wide Moat Stocks On Sale - The September 2020 Heat Map

Incyte

Biotech Industry Near-Term Outlook Modest Amid Coronavirus

Anti-Amyloid Drugs: The Advantages Of Alzheon's ALZ-801 Over Biogen's Aducanumab

The short interest data are out for August 14, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Major Biotechs Scare Off Short Sellers

News for Biogen Stock (BIIB)